

# Conjunctivitis Market to Reach \$7.2 Billion, Globally, by 2033 at 4.1% CAGR: Allied Market Research

*The global conjunctivitis market size was valued at \$4.8 billion in 2023, and is projected to reach \$7.2 billion by 2033, growing at a CAGR of 4.1%.*



PORTLAND, OR, UNITED STATES, December 17, 2024 /EINPresswire.com/ -- Allied Market Research published a report, titled, "[Conjunctivitis Market](#) by Type (Diagnosis and Treatment), by Disease Type (Allergic Conjunctivitis, Bacterial Conjunctivitis and Viral Conjunctivitis), and End User (Hospitals and Clinics, Specialty Eye Clinics and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the conjunctivitis market was valued at \$4.8 billion in 2023, and is estimated to reach \$7.2 billion by 2033, growing at a CAGR of 4.1% from 2024 to 2033.

□□□□□□ □□□□□□ □□□□ □□ □□□□□□ -

<https://www.alliedmarketresearch.com/request-sample/A324393>

## Prime determinants of growth

Increase in prevalence of conjunctivitis, rise in awareness about early diagnosis & treatment, and increase in R&D activities for the development of conjunctivitis treatment are the major factors that drive the growth of the conjunctivitis market. However, the side effects associated with conjunctivitis drugs restrict market growth. Moreover, high growth potential in developing economies offers remunerative opportunities for the expansion of the global conjunctivitis market.

## Segment Highlights

The treatment segment held the highest market share in 2023.

By type, the treatment segment accounted for the largest share of the market in 2023. The dominance of this segment is attributed to its effectiveness in managing symptoms of allergic conjunctivitis, which include itching, redness, and swelling caused by allergens such as pollen and pet dander. In addition, their widespread availability in various formulations, including eye drops and oral medications, enhances patient compliance and treatment efficacy, thereby boosting segment growth.

The allergic conjunctivitis segment held the highest market share in 2023.

By disease type, the allergic conjunctivitis segment dominated the market in 2023 owing to increase in prevalence of allergic conjunctivitis. In addition, rise in environmental allergens and surge in awareness among patients and healthcare providers have fueled demand for effective treatments, including antihistamines and mast cell stabilizers, driving segment growth.

The hospital and clinics segment has significant role in market

By end user, the hospital and clinics segment plays a significant role in market as hospital and clinics are equipped enough to dispense a wide range of prescription medications, including advanced anti-infectives and anti-allergic drugs. In addition, they provide specialized care, access to advanced diagnostic tools, and effective treatment options, driving significant market demand. Further, the emphasis on patient safety and infection control in these settings enhances the importance of their role in managing conjunctivitis.

For more information on this market, visit our website (https://www.alliedmarketresearch.com/conjunctivitis-market/purchase-options)

@

<https://www.alliedmarketresearch.com/conjunctivitis-market/purchase-options>

## Regional Outlook

North America held the largest market share in 2023.

North America accounted for the largest market share in the conjunctivitis market in 2023 and is expected to retain its dominance throughout the forecast period. This is primarily attributed to a well-established healthcare infrastructure and high healthcare expenditure, facilitating access to advanced diagnostic and treatment options. In addition, rise in awareness of eye health, surge in importance of early treatment among the population, presence of leading pharmaceutical companies, and ongoing R&D activities contribute to market growth in this region.

## Major Key Players -

AbbVie Inc.

Ajanta Pharma Limited

AFT Pharmaceuticals

Alembic Pharmaceuticals Ltd

Bausch Health Companies Inc

Cipla, Inc.

Grevis Pharmaceutical Private Limited

Indoco Remedies Ltd.

Johnson & Johnson Services Inc

Novartis AG

The report provides a detailed analysis of these key players in the global conjunctivitis market. These players have adopted different strategies such as agreement, product launch, and product approval to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to highlight the competitive scenario.

#### Recent Developments in Conjunctivitis Industry

In January 2022, Sun Pharma announced the launch of CEQUA in Canada. It is used to treat dry eye disease.

In February 2021, Bausch + Lomb announced the U.S. launch of its of Alaway preservative free (ketotifen fumarate ophthalmic solution 0.035%) antihistamine eye drops, the first and only over the counter (OTC) preservative-free antihistamine eye itch relief drop.

For more information, contact us at [info@alliedmarketresearch.com](mailto:info@alliedmarketresearch.com) -

<https://www.alliedmarketresearch.com/purchase-enquiry/A324393>

#### Frequently Asked Questions?

Q1. What is the total market value of conjunctivitis market report ?

Q2. What would be forecast period in the market report?

Q3. What are the key trends in the conjunctivitis market report?

Q4. What factors are driving the growth of the conjunctivitis market?

Q5. What is the market value of conjunctivitis market in 2033?

Q6. Which is the largest regional market for conjunctivitis?

Q7. What is conjunctivitis?

□ □□□□□□□□ □□□□□□ □□□□□□ □□□□ □□□□□□ □□□□□□□□ -

Wearable Injectors Market - <https://www.alliedmarketresearch.com/wearable-injectors-market>

Europe Digital Therapeutics Market - <https://www.alliedmarketresearch.com/europe-digital-therapeutics-market-A06151>

Personal Mobility Devices Market - <https://www.alliedmarketresearch.com/personal-mobility-devices-market-A11117>

Medical Electrodes Market - <https://www.alliedmarketresearch.com/medical-electrodes-market>

Disposable Medical Gloves Market - <https://www.alliedmarketresearch.com/disposable-medical-gloves-market>

About Us -

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

Pawan Kumar, the CEO of Allied Market Research, is leading the organization toward providing high-quality data and insights. We are in professional corporate relations with various research data tables and confirms utmost accuracy in our market forecasting. Each and every us companies and this helps us in digging out market data that helps us generate accurate y data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

David Correa

Allied Market Research

+1 800-792-5285

[email us here](#)

Visit us on social media:

[Facebook](#)

[X](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/769653535>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.